AUTL Company Profile and Key Details
Autolus Therapeutics plc
AUTL Stock Price Chart
Stock Price Today
Autolus Therapeutics plc (AUTL) stock surged +0.45%, trading at $2.21 on NASDAQ, up from the previous close of $2.20. The stock opened at $2.21, fluctuating between $2.17 and $2.26 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Company Information
| Employees | 463 |
| Beta | 2.04 |
| Sales or Revenue | $1.70M |
| 5Y Sales Change% | -0.855% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Autolus Therapeutics plc (NASDAQ: AUTL) stock price is $2.21 in the last trading session. During the trading session, AUTL stock reached the peak price of $2.26 while $2.17 was the lowest point it dropped to. The percentage change in AUTL stock occurred in the recent session was 0.45% while the dollar amount for the price change in AUTL stock was $0.01.
The NASDAQ listed AUTL is part of Biotechnology industry that operates in the broader Healthcare sector. Autolus Therapeutics plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Olivia Manser
Director of Investor Relations
Dr. Christian Martin Itin Ph.D.
Chief Executive Officer & Director
Mr. David Brochu
Senior Vice President & Chief Technical Officer
Mr. Brent Rice
Senior Vice President, Chief Commercial Officer & Site Head of US
Dr. Martin Pule M.D., MBBS
Founder, Senior Vice President & Chief Scientific Officer
Dr. Lucinda Crabtree Ph.D.
Senior Vice President & Chief Financial Officer
Mr. Christopher Vann
Senior Vice President & Chief Operating Officer
Dr. Chris Williams
Senior Vice President of Corporation Devel.
Mr. Robert F. Dolski
Chief Financial Officer
Mr. Alexander Swan
Senior Vice President, HR & Internal Communications
Mr. Andrew J. Oakley ACA, BEcon, MBA
Senior Advisor
Dr. Edgar E. W. Braendle M.D., Ph.D.
Senior Vice President & Chief Devel. Officer
AUTL's closing price is 6.76% higher than its 52-week low of $2.07 where as its distance from 52-week high of $7.37 is -70.01%.
Number of AUTL employees currently stands at 463.
Official Website of AUTL is: https://www.autolus.com
AUTL could be contacted at phone 442 038 296230 and can also be accessed through its website. AUTL operates from The MediaWorks, London, W12 7FP, United Kingdom.
AUTL stock volume for the day was 1.02M shares. The average number of AUTL shares traded daily for last 3 months was 1.77M.
The market value of AUTL currently stands at $588.12M with its latest stock price at $2.21 and 266.12M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com